Business Context and Reporting Period
This Form 6-K filing by Takeda Pharmaceutical Company Limited, dated June 12, 2025, reports on share repurchase activities for the period from May 1, 2025, to May 31, 2025. The document serves as a translation of the company's Share Repurchase Report filed with the Kanto Local Finance Bureau under Japanese law.
Key Financial Metrics
The filing focuses exclusively on capital allocation via share buybacks and does not provide operational financial metrics such as revenue, profit, cash flow, margins, or debt levels.
- Repurchase Program Authorization: Board resolution approved on January 30, 2025, for a total amount of 100,000,000,000 JPY.
- Program Period: February 17, 2025, to May 31, 2025.
- Repurchases in Reporting Month (May 2025): 0 shares; 0 JPY.
- Cumulative Repurchases (as of May 31, 2025): 23,367,100 shares totaling 99,955,865,500 JPY.
- Program Progress: 81.99% of authorized shares and 99.96% of authorized value completed.
- Treasury Shares Held (as of May 31, 2025): 23,558,168 shares.
- Total Issued Shares: 1,590,961,709 shares.
Material Changes
No repurchase activity occurred during the reporting month of May 2025. The filing notes that the acquisition of shares under the current Board resolution was effectively completed on April 23, 2025 (settlement date basis), resulting in no new transactions in May.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It does not disclose specific risks or contingencies beyond the standard regulatory context of the share repurchase program. The method of acquisition is specified as open-market repurchase through a trust bank.
Key Facts for Investor Verification
- Verify that the share repurchase program authorized in January 2025 is considered complete as of April 23, 2025, with no further buybacks expected under this specific resolution.
- Confirm the total number of treasury shares held (23,558,168) excludes shares held by the ESOP trust account and the BIP trust account.
- Note that the filing does not contain operational financial results; investors should refer to the company's Form 20-F or quarterly earnings releases for revenue and profit data.